PharmaMar's profits rebound with a 64% increase to 2.3 million euros in Q1 2024 compared to the same period last year. Total revenues dropped by 19.45%...
PharmaMar started February with falls of almost 3% at the opening of the market. The reason was that Sylentis had failed in its primary objective of...